FN1
Summary: This gene encodes fibronectin, a glycoprotein present in a soluble dimeric form in plasma, and in a dimeric or multimeric form at the cell surface and in extracellular matrix. The encoded preproprotein is proteolytically processed to generate the mature protein. Fibronectin is involved in cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis. The gene has three regions subject to alternative splicing, with the potential to produce 20 different transcript variants, at least one of which encodes an isoform that undergoes proteolytic processing. The full-length nature of some variants has not been determined. [provided by RefSeq, Jan 2016].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| fibronectin 1 | MIM:135600 | Ensembl:ENSG00000115414 | HGNC:HGNC:3778 | PA28194 | 2q35 |
GO terms in FN1
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| CC | HDA | GO:0005576 | extracellular region |
| CC | NAS | GO:0005576 | extracellular region |
| CC | TAS | GO:0005576 | extracellular region |
| CC | IDA | GO:0005577 | fibrinogen complex |
| CC | HDA | GO:0005615 | extracellular space |
| CC | IDA | GO:0005615 | extracellular space |
| CC | TAS | GO:0005788 | endoplasmic reticulum lumen |
| CC | IDA | GO:0005793 | endoplasmic reticulum-Golgi intermediate compartment |
| CC | IEA | GO:0016324 | apical plasma membrane |
| CC | HDA | GO:0031012 | extracellular matrix |
| CC | IDA | GO:0031012 | extracellular matrix |
| CC | TAS | GO:0031093 | platelet alpha granule lumen |
| CC | HDA | GO:0062023 | collagen-containing extracellular matrix |
| CC | HDA | GO:0062023 | collagen-containing extracellular matrix |
| CC | IDA | GO:0062023 | collagen-containing extracellular matrix |
| CC | ISS | GO:0062023 | collagen-containing extracellular matrix |
| CC | HDA | GO:0070062 | extracellular exosome |
| CC | IDA | GO:0070062 | extracellular exosome |
| CC | HDA | GO:0072562 | blood microparticle |
| BP | IEA | GO:0001525 | angiogenesis |
| BP | IDA | GO:0001932 | regulation of protein phosphorylation |
| BP | TAS | GO:0002576 | platelet degranulation |
| BP | IEA | GO:0006953 | acute-phase response |
| BP | IEA | GO:0007044 | cell-substrate junction assembly |
| BP | NAS | GO:0007155 | cell adhesion |
| BP | IEA | GO:0007161 | calcium-independent cell-matrix adhesion |
| BP | IDA | GO:0008284 | positive regulation of cell proliferation |
| BP | IEA | GO:0008360 | regulation of cell shape |
| BP | NAS | GO:0009611 | response to wounding |
| BP | IDA | GO:0010628 | positive regulation of gene expression |
| BP | IEA | GO:0010952 | positive regulation of peptidase activity |
| BP | IDA | GO:0018149 | peptide cross-linking |
| BP | TAS | GO:0019221 | cytokine-mediated signaling pathway |
| BP | TAS | GO:0030198 | extracellular matrix organization |
| BP | IMP | GO:0033622 | integrin activation |
| BP | IDA | GO:0034446 | substrate adhesion-dependent cell spreading |
| BP | IMP | GO:0034446 | substrate adhesion-dependent cell spreading |
| BP | IDA | GO:0035987 | endodermal cell differentiation |
| BP | IEA | GO:0042060 | wound healing |
| BP | TAS | GO:0043687 | post-translational protein modification |
| BP | TAS | GO:0044267 | cellular protein metabolic process |
| BP | IEA | GO:0045773 | positive regulation of axon extension |
| BP | IDA | GO:0048146 | positive regulation of fibroblast proliferation |
| BP | TAS | GO:0050900 | leukocyte migration |
| BP | IDA | GO:0051702 | interaction with symbiont |
| BP | IDA | GO:0052047 | interaction with other organism via secreted substance involved in symbiotic interaction |
| BP | IDA | GO:0070372 | regulation of ERK1 and ERK2 cascade |
| BP | IDA | GO:1901166 | neural crest cell migration involved in autonomic nervous system development |
| BP | IDA | GO:1904237 | positive regulation of substrate-dependent cell migration, cell attachment to substrate |
| BP | IDA | GO:2001202 | negative regulation of transforming growth factor-beta secretion |
| MF | IPI | GO:0002020 | protease binding |
| MF | IPI | GO:0005102 | signaling receptor binding |
| MF | IDA | GO:0005178 | integrin binding |
| MF | IMP | GO:0005178 | integrin binding |
| MF | IPI | GO:0005178 | integrin binding |
| MF | IPI | GO:0005515 | protein binding |
| MF | NAS | GO:0005518 | collagen binding |
| MF | IPI | GO:0008022 | protein C-terminus binding |
| MF | NAS | GO:0008201 | heparin binding |
| MF | IEA | GO:0016504 | peptidase activator activity |
| MF | IPI | GO:0019899 | enzyme binding |
| MF | IPI | GO:0042802 | identical protein binding |
| MF | IPI | GO:0051087 | chaperone binding |
| MF | IPI | GO:0097718 | disordered domain specific binding |
Gene expression in normal tissue: FN1
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in FN1
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-109582 | Hemostasis |
| reactome | R-HSA-114608 | Platelet degranulation |
| reactome | R-HSA-1280215 | Cytokine Signaling in Immune system |
| reactome | R-HSA-1474228 | Degradation of the extracellular matrix |
| reactome | R-HSA-1474228 | Degradation of the extracellular matrix |
| reactome | R-HSA-1474244 | Extracellular matrix organization |
| reactome | R-HSA-1474244 | Extracellular matrix organization |
| reactome | R-HSA-1566948 | Elastic fibre formation |
| reactome | R-HSA-1566977 | Fibronectin matrix formation |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-168256 | Immune System |
| reactome | R-HSA-202733 | Cell surface interactions at the vascular wall |
| reactome | R-HSA-2129379 | Molecules associated with elastic fibres |
| reactome | R-HSA-216083 | Integrin cell surface interactions |
| reactome | R-HSA-3000170 | Syndecan interactions |
| reactome | R-HSA-3000171 | Non-integrin membrane-ECM interactions |
| reactome | R-HSA-3000178 | ECM proteoglycans |
| reactome | R-HSA-354192 | Integrin alphaIIb beta3 signaling |
| reactome | R-HSA-354194 | GRB2:SOS provides linkage to MAPK signaling for Integrins |
| reactome | R-HSA-372708 | p130Cas linkage to MAPK signaling for integrins |
| reactome | R-HSA-381426 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) |
| reactome | R-HSA-392499 | Metabolism of proteins |
| reactome | R-HSA-449147 | Signaling by Interleukins |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5673001 | RAF/MAP kinase cascade |
| reactome | R-HSA-5674135 | MAP2K and MAPK activation |
| reactome | R-HSA-5683057 | MAPK family signaling cascades |
| reactome | R-HSA-5684996 | MAPK1/MAPK3 signaling |
| reactome | R-HSA-597592 | Post-translational protein modification |
| reactome | R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling |
| reactome | R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants |
| reactome | R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants |
| reactome | R-HSA-6802949 | Signaling by RAS mutants |
| reactome | R-HSA-6802952 | Signaling by BRAF and RAF fusions |
| reactome | R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF |
| reactome | R-HSA-6802957 | Oncogenic MAPK signaling |
| reactome | R-HSA-6806834 | Signaling by MET |
| reactome | R-HSA-76002 | Platelet activation, signaling and aggregation |
| reactome | R-HSA-76005 | Response to elevated platelet cytosolic Ca2+ |
| reactome | R-HSA-76009 | Platelet Aggregation (Plug Formation) |
| reactome | R-HSA-8874081 | MET activates PTK2 signaling |
| reactome | R-HSA-8875878 | MET promotes cell motility |
| reactome | R-HSA-8957275 | Post-translational protein phosphorylation |
| reactome | R-HSA-9006921 | Integrin signaling |
| reactome | R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases |
| pid | angiopoietinreceptor_pathway | Angiopoietin receptor Tie2-mediated signaling |
| pid | avb3_integrin_pathway | Integrins in angiogenesis |
| pid | integrin1_pathway | Beta1 integrin cell surface interactions |
| pid | integrin3_pathway | Beta3 integrin cell surface interactions |
| pid | integrin5_pathway | Beta5 beta6 beta7 and beta8 integrin cell surface interactions |
| pid | integrin_a4b1_pathway | Alpha4 beta1 integrin signaling events |
| pid | integrin_a9b1_pathway | Alpha9 beta1 integrin signaling events |
| pid | lymphangiogenesis_pathway | VEGFR3 signaling in lymphatic endothelium |
| pid | syndecan_2_pathway | Syndecan-2-mediated signaling events |
| pid | syndecan_4_pathway | Syndecan-4-mediated signaling events |
| pid | upa_upar_pathway | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling |
| kegg | hsa04151 | PI3K-Akt signaling pathway - Homo sapiens (human) |
| kegg | hsa04510 | Focal adhesion - Homo sapiens (human) |
| kegg | hsa04512 | ECM-receptor interaction - Homo sapiens (human) |
| kegg | hsa04810 | Regulation of actin cytoskeleton - Homo sapiens (human) |
| kegg | hsa04933 | AGE-RAGE signaling pathway in diabetic complications - Homo sapiens (human) |
| kegg | hsa05100 | Bacterial invasion of epithelial cells - Homo sapiens (human) |
| kegg | hsa05146 | Amoebiasis - Homo sapiens (human) |
| kegg | hsa05165 | Human papillomavirus infection - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05205 | Proteoglycans in cancer - Homo sapiens (human) |
| kegg | hsa05222 | Small cell lung cancer - Homo sapiens (human) |
| wikipathways | WP2911 | miRNA targets in ECM and membrane receptors |
| wikipathways | WP306 | Focal Adhesion |
| wikipathways | WP3287 | Overview of nanoparticle effects |
| wikipathways | WP3303 | Rac1-Pak1-p38-MMP-2 pathway |
| wikipathways | WP366 | TGF-beta Signaling Pathway |
| wikipathways | WP3670 | Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway |
| wikipathways | WP3680 | Association Between Physico-Chemical Features and Toxicity Associated Pathways |
| wikipathways | WP3859 | TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition |
| wikipathways | WP3932 | Focal Adhesion-PI3K-Akt-mTOR-signaling pathway |
| wikipathways | WP3967 | miR-509-3p alteration of YAP1-ECM axis |
| wikipathways | WP4066 | Interleukin-4 and 13 signaling |
| wikipathways | WP4172 | PI3K-Akt Signaling Pathway |
| wikipathways | WP4239 | EMT transition in Colorectal Cancer |
| wikipathways | WP453 | Inflammatory Response Pathway |
| wikipathways | WP51 | Regulation of Actin Cytoskeleton |
| wikipathways | WP615 | Senescence and Autophagy in Cancer |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD690 | PRIMA-1MET | 3 |
| iGMDRD60 | Quinoclamine | 3 |
| iGMDRD369 | TGX-115 | 3 |
| iGMDRD64 | Parbendazole | 3 |
| iGMDRD268 | Cerulenin | 3 |
| iGMDRD23 | Gossypol | 3 |
| iGMDRD188 | Piperlongumine | 6 |
| iGMDRD100 | Zebularine | 3 |
| iGMDRD399 | Selumetinib | 2 |
| iGMDRD577 | BIX01294 | 5 |
| iGMDRD398 | Sepantronium | 3 |
| iGMDRD801 | 2,4-dideoxy-DC-45-A2 | 3 |
| iGMDRD318 | PAC-1 | 9 |
| iGMDRD247 | Blebbistatin | 3 |
| iGMDRD474 | Avrainvillamide | 3 |
| iGMDRD138 | PX 12 | 3 |
| iGMDRD802 | 4-methylfasudil | 3 |
| iGMDRD260 | FQI-2 | 3 |
| iGMDRD280 | CYTOCHALASIN B | 3 |
| iGMDRD634 | SCHEMBL2608041 | 3 |
| iGMDRD380 | Pifithrin-alpha | 3 |
| iGMDRD446 | LY 2183240 | 5 |
| iGMDRD144 | NSC95397 | 3 |
| iGMDRD483 | SCH-529074 | 3 |
| iGMDRD781 | Sirolimus | 2 |
| iGMDRD151 | CHM-1 | 3 |
| iGMDRD387 | CHIR-99021 | 3 |
| iGMDRD889 | Compound 7d-cis | 3 |
| iGMDRD772 | BRD4770 | 3 |
| iGMDRD300 | Tozasertib | 5 |
| iGMDRD552 | AZD-1775 | 3 |
| iGMDRD872 | BRD7137 | 3 |
| iGMDRD662 | JQ-1 | 1 |
| iGMDRD329 | Merck60 | 3 |
| iGMDRD213 | SMR000068650 | 3 |
| iGMDRD103 | SN-38 | 1 |
| iGMDRD558 | CAY10603 | 1 |
| iGMDRD154 | NSC23766 | 3 |
| iGMDRD351 | GW843682X | 2 |
| iGMDRD219 | Bax channel blocker | 3 |
| iGMDRD607 | Ubistatin B | 5 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in FN1
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.